These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31753110)

  • 1. Principles of Immunotherapy in Melanoma.
    Onitilo AA; Wittig JA
    Surg Clin North Am; 2020 Feb; 100(1):161-173. PubMed ID: 31753110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for melanoma.
    Cuevas LM; Daud AI
    Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory cytokines as therapeutic agents for melanoma.
    Nicholas C; Lesinski GB
    Immunotherapy; 2011 May; 3(5):673-90. PubMed ID: 21554095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Targets for the Treatment of Melanoma.
    Ambrosi L; Khan S; Carvajal RD; Yang J
    Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in melanoma.
    Feld E; Mitchell TC
    Immunotherapy; 2018 Aug; 10(11):987-998. PubMed ID: 30149766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].
    Moura B; Homicsko K; Berthod G; Cerottini JP; Guggisberg D; Gaide O; Maillard MH; Michielin O
    Rev Med Suisse; 2015 May; 11(475):1108, 1110-4. PubMed ID: 26152085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
    Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
    Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses.
    Qu Q; Zhai Z; Xu J; Li S; Chen C; Lu B
    Front Immunol; 2020; 11():634. PubMed ID: 32351508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
    Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
    Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
    Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
    Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of malignant melanoma.
    Leong SP
    Surg Clin North Am; 1996 Dec; 76(6):1355-81. PubMed ID: 8977556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of patients with metastatic melanoma.
    Yu Z; Si L
    Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
    Eggermont AM; Maio M; Robert C
    Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.